SCHEMBL31269029

SCHEMBL31269029

Cc1cnc(Cn2c(-c3ccc(OCCN4CC[C@@H](O)C4)cc3Cl)nc3c(OC4(C)CC4)ncnc32)s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 2/20 0.37
▸ PSEN1 P49768 2/20 0.35
▸ PSEN2 P49810 2/20 0.35
▸ APH1B Q8WW43 2/20 0.35
▸ NCSTN Q92542 2/20 0.35
▸ APH1A Q96BI3 2/20 0.35
▸ PSENEN Q9NZ42 2/20 0.35
▸ PIK3CD O00329 2/20 0.35
▸ LTA4H P09960 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ DRD2 P14416 3/20 0.32
▸ ALK Q9UM73 1/20 0.32
▸ ESR1 P03372 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.31
▸ EGFR P00533 1/20 0.31
▸ ERBB2 P04626 1/20 0.31
▸ HRH4 Q9H3N8 1/20 0.31
▸ PDCD1 Q15116 2/20 0.30
▸ CD274 Q9NZQ7 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268848 0.97 HRH3 (0.35) PDK2PSEN1PSEN2APH1BNCSTN
SCHEMBL31269378 0.95 PIK3CD (0.34) PDK2PSEN1PSEN2APH1BNCSTN
SCHEMBL31268781 0.92 HRH4 (0.34) PIK3CDHRH3HRH4
SCHEMBL31269171 0.90 DRD2 (0.37) PIK3CDKDM4EDRD2ESR1ESR2
SCHEMBL30983391 0.89 LTA4H (0.43) PDK2PSEN1PSEN2APH1BNCSTN
SCHEMBL30983472 0.89 PDE2A (0.37) PIK3CDKDM4EDRD2ALKESR1
SCHEMBL31269094 0.87 PDK2 (0.37) PDK2PSEN1PSEN2APH1BNCSTN
SCHEMBL30983550 0.87 PDK2 (0.37) PDK2PSEN1PSEN2APH1BNCSTN
SCHEMBL31269323 0.87 HRH4 (0.40) PIK3CDKDM4EDRD2ALKESR1
SCHEMBL30983392 0.85 DRD2 (0.40) PDK2PIK3CDLTA4HKDM4EDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback